Increase Practice Revenue with AdaptDx
As the only dark adaptation test used quickly and effectively in a clinical setting, AdaptDx® enhances your diagnostic ability and dramatically increases your practice revenue.
AdaptDx is Reimbursable
- CPT Code 92284 for dark adaptation
- $64.08 average national reimbursement
- No limit to number of tests per year
- Monocular testing qualifies for full reimbursement
- Multiple ICD-10 codes for screening and monitoring (including H53.62 for Acquired Night Blindness)
AdaptDx Drives Additional Revenue
Identifying patients with subclinical AMD offers the opportunity to schedule additional testing and more frequent exams to help manage the disease. AdaptDx is co-billable with OCT, imaging and/or visual field.
Not only does it increase revenue from auxiliary assessments, identifying AMD patients through dark adaptation testing elicits extra income from sales of nutraceuticals, blue light blocking lenses and protective sunglasses.
AdaptDx more than paid for itself within the first few months.
AdaptDx Helps Detect Additional AMD Patients
By testing your patients with AdaptDx, you will most likely uncover several new cases of subclinical and early AMD. In fact, current users see as many as 30-40% of patients with night vision complaints fail the AdaptDx Rapid Test—indicating an AMD diagnosis with 90% accuracy.
Once AMD is detected, dark adaptation testing allows you to monitor disease progression at regular intervals. In turn, more frequent visits and proactive treatment often results in improved outcomes and patient compliance—along with boosting practice revenue.
Practicing with AdaptDx
Dr. Gary Kirman shares his experience with the AdaptDx dark adaptometer and how it helped him to manage his AMD patients and increase practice revenue.